Grassley Wants An Rx Safety Reorganization; Can FDA Keep Him At Bay Again? Congressional Avandia Investigation Reopens Door On Splitting CDER
Executive Summary
Renewed congressional interest in a separate drug safety center at FDA is a likely off-shoot of a Senate Finance Committee report that questions GlaxoSmithKline's handling of cardiovascular safety issues surrounding Avandia
You may also be interested in...
Avandia Committee Gives Split Vote To Drug, But FDA Clear Winner
A re-adjudication of cardiovascular events in the RECORD trial reassured members of a June 5-6 advisory committee that the study findings are reliable, but did not erase uncertainties about CV risk associated with rosiglitazone.
Grassley And Baucus Turn Up Heat On GSK With Attack On Avandia Data Handling
Company's internal e-mails suggest GSK hid vital studies related to safety of Avandia relative to competitor, senators charge.
Avandia Aftershocks: Will FDA Drug Safety Review Structures Crumble?
Rep. Rosa DeLauro's, D-Conn., hearing on the safety of GlaxoSmithKline's diabetes drug Avandia has ratcheted up the pressure on FDA to make broad reforms of its review structure, but the congresswoman has been careful not to urge a particular course of action for the agency